NMDA-enhancer medicine tested for schizophrenia without antipsychotics
Treatments studied
Part of Mental health clinical trials.
This Phase 2 trial tests a single medicine intended to help people with schizophrenia who cannot take standard antipsychotic medications due to side effects or poor response. It may help reduce schizophrenia symptoms, but whether you can join depends on your diagnosis, medication history, and health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a schizophrenia diagnosis based on DSM-5 criteria
- You are refusing or unable to tolerate antipsychotic medicines because they didn’t work or caused side effects
- Your symptom score (PANSS total) is 60 or higher
- You have not taken antipsychotic medicine for at least 1 week
- You are willing to sign consent and follow study visits and instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication that boosts brain NMDA receptors can improve negative symptoms in schizophrenia, and looks at differences between men and women. It is for people with stable schizophrenia who still have mostly flat mood or low motivation.
This study tests a new treatment that may help with thinking and memory problems in people with schizophrenia. It is for people whose schizophrenia symptoms are stable and who are already on a steady medication.
This Phase 2 trial tests whether adding an “NMDA-enhancing” treatment plus an antioxidant can improve ongoing schizophrenia symptoms over 12 weeks. It’s meant for people who still have symptoms even though their usual antipsychotic dose has been stable for at least 3 months.
This trial tests a combination of an NMDA-targeting medicine and an anti-inflammatory treatment for people with schizophrenia that has not responded well to several standard treatments, including clozapine. If you qualify, the goal is to see whether this combination improves symptoms more than usual care.
This trial tests whether combining an NMDA “signal-supporting” treatment with an anti-inflammatory medicine can reduce symptoms in people with schizophrenia who don’t respond well to usual antipsychotic drugs. If you’ve tried at least two antipsychotics and you’re still symptomatic, this study may be worth screening for.
This trial tests an experimental combination treatment that targets two different brain receptors (sigma-1 and NMDA) to see if it can improve symptoms in people with schizophrenia that hasn't responded well to standard antipsychotics.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.